Celltrion Inc receives Investment Bank Analyst Rating Update
SEOUL (Reuters) - South Korea's Celltrion Inc (KS:068270) on Thursday said British regulators had given it regulatory approval for a phase I clinical trial of its experimental...
By Junko Fujita and Rocky Swift TOKYO (Reuters) - Blackstone, Bain Capital and Taisho Pharmaceutical are among the final bidders for Takeda Pharmaceutical's (T:4502) consumer drug...
Reddit-hyped stocks slump Alphabet, Amazon beat on earnings Tech leads reflation trade rally Key EventsUS futures contracts on the Dow, S&P, NASDAQ, and European stocks advanced...
Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.
|Moving Averages||Strong Sell||Strong Sell||Strong Sell||Neutral||Buy|
|Technical Indicators||Strong Sell||Strong Sell||Strong Sell||Sell||Buy|
|Summary||Strong Sell||Strong Sell||Strong Sell||Neutral||Buy|